DISC MEDICINE INC. - COMMON STOCK

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

22 Jan 2025 20:35:43 By Nasdaq GlobeNewswire

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

21 Jan 2025 15:01:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

21 Jan 2025 06:45:00 By Nasdaq GlobeNewswire

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

20 Jan 2025 18:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

17 Jan 2025 15:00:00 By Nasdaq GlobeNewswire

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

09 Dec 2024 11:00:00 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

08 Dec 2024 19:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

13 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

08 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

04 Nov 2024 06:50:00 By Nasdaq GlobeNewswire

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

01 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

25 Oct 2024 12:00:00 By Nasdaq GlobeNewswire

Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

11 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

19 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

30 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire